These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 11870832)
1. Assessment of T1 and T2* effects in vivo and ex vivo using iron oxide nanoparticles in steady state--dependence on blood volume and water exchange. Bjørnerud A; Johansson LO; Briley-Saebø K; Ahlström HK Magn Reson Med; 2002 Mar; 47(3):461-71. PubMed ID: 11870832 [TBL] [Abstract][Full Text] [Related]
2. Quantitative renal cortical perfusion in human subjects with magnetic resonance imaging using iron-oxide nanoparticles: influence of T1 shortening. Morell A; Ahlstrom H; Schoenberg SO; Abildgaard A; Bock M; Bjørnerud A Acta Radiol; 2008 Oct; 49(8):955-62. PubMed ID: 18615336 [TBL] [Abstract][Full Text] [Related]
3. Renal T(*)(2) perfusion using an iron oxide nanoparticle contrast agent--influence of T(1) relaxation on the first-pass response. Bjørnerud A; Johansson LO; Ahlström HK Magn Reson Med; 2002 Feb; 47(2):298-304. PubMed ID: 11810673 [TBL] [Abstract][Full Text] [Related]
4. Long-term imaging effects in rat liver after a single injection of an iron oxide nanoparticle based MR contrast agent. Briley-Saebø K; Hustvedt SO; Haldorsen A; Bjørnerud A J Magn Reson Imaging; 2004 Oct; 20(4):622-31. PubMed ID: 15390223 [TBL] [Abstract][Full Text] [Related]
5. Assessment of myocardial blood volume and water exchange: theoretical considerations and in vivo results. Bjørnerud A; Bjerner T; Johansson LO; Ahlström HK Magn Reson Med; 2003 May; 49(5):828-37. PubMed ID: 12704765 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of a new ultrasmall superparamagnetic iron oxide contrast agent Clariscan, (NC100150) for MRI of renal perfusion: experimental study in an animal model. Bachmann R; Conrad R; Kreft B; Luzar O; Block W; Flacke S; Pauleit D; Träber F; Gieseke J; Saebo K; Schild H J Magn Reson Imaging; 2002 Aug; 16(2):190-5. PubMed ID: 12203767 [TBL] [Abstract][Full Text] [Related]
7. Frequency dependence of MR relaxation times. II. Iron oxides. Bulte JW; Vymazal J; Brooks RA; Pierpaoli C; Frank JA J Magn Reson Imaging; 1993; 3(4):641-8. PubMed ID: 8347958 [TBL] [Abstract][Full Text] [Related]
8. T1 and T2 relaxivity of intracellular and extracellular USPIO at 1.5T and 3T clinical MR scanning. Simon GH; Bauer J; Saborovski O; Fu Y; Corot C; Wendland MF; Daldrup-Link HE Eur Radiol; 2006 Mar; 16(3):738-45. PubMed ID: 16308692 [TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics of the lymphotropic nanoparticle MRI contrast agent ferumoxtran-10. Islam T; Wolf G Cancer Biomark; 2009; 5(2):69-73. PubMed ID: 19414923 [TBL] [Abstract][Full Text] [Related]
10. Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging. Briley-Saebo K; Bjørnerud A; Grant D; Ahlstrom H; Berg T; Kindberg GM Cell Tissue Res; 2004 Jun; 316(3):315-23. PubMed ID: 15103550 [TBL] [Abstract][Full Text] [Related]
11. Recent advances in iron oxide nanocrystal technology for medical imaging. Corot C; Robert P; Idée JM; Port M Adv Drug Deliv Rev; 2006 Dec; 58(14):1471-504. PubMed ID: 17116343 [TBL] [Abstract][Full Text] [Related]
12. Comparison of Three Ultrasmall, Superparamagnetic Iron Oxide Nanoparticles for MRI at 3.0 T. Colbert CM; Ming Z; Pogosyan A; Finn JP; Nguyen KL J Magn Reson Imaging; 2023 Jun; 57(6):1819-1829. PubMed ID: 36250695 [TBL] [Abstract][Full Text] [Related]
13. Quantitative assessment of uptake and distribution of iron oxide particles (NC100150) in human melanoma xenografts by contrast-enhanced MRI. Graff BA; Vangberg L; Rofstad EK Magn Reson Med; 2004 Apr; 51(4):727-35. PubMed ID: 15065245 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of nonperfused myocardial ischemia with MRI and an intravascular USPIO contrast agent in an ex vivo pig model. Bjerner T; Ericsson A; Wikström G; Johansson L; Nilsson S; Ahlström H; Hemmingsson A J Magn Reson Imaging; 2000 Dec; 12(6):866-72. PubMed ID: 11105024 [TBL] [Abstract][Full Text] [Related]
16. Pre-clinical results with Clariscan (NC100150 Injection); experience from different disease models. Bjørnerud A; Johansson LO; Ahlström HK MAGMA; 2001 May; 12(2-3):99-103. PubMed ID: 11390264 [TBL] [Abstract][Full Text] [Related]
17. Characterization of t1 relaxation and blood-myocardial contrast enhancement of NC100150 injection in cardiac MRI. Wagenseil JE; Johansson LO; Lorenz CH J Magn Reson Imaging; 1999 Nov; 10(5):784-9. PubMed ID: 10548789 [TBL] [Abstract][Full Text] [Related]
18. In and ex vivo MR evaluation of acute myocardial ischemia in pigs by determining R1 in steady state after the administration of the intravascular contrast agent NC100150 injection. Bjerner T; Johansson L; Wikström G; Ericsson A; Briley-Soebo K; Bjørnerud A; Ahlström H Invest Radiol; 2004 Aug; 39(8):479-86. PubMed ID: 15257209 [TBL] [Abstract][Full Text] [Related]
19. Off-resonance saturation as a means of generating contrast with superparamagnetic nanoparticles. Zurkiya O; Hu X Magn Reson Med; 2006 Oct; 56(4):726-32. PubMed ID: 16941618 [TBL] [Abstract][Full Text] [Related]